| Original language | English (US) |
|---|---|
| Pages (from-to) | e353-e355 |
| Journal | Haemophilia |
| Volume | 26 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2020 |
ASJC Scopus subject areas
- Hematology
- Genetics(clinical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Haemophilia, Vol. 26, No. 6, 11.2020, p. e353-e355.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage
AU - Bush, Kelly A.
AU - Lucas, Tiffany L.
AU - Haley, Kristina M.
AU - Thornburg, Courtney D.
N1 - Funding Information: Thank you to the family who allowed us to share this case and to the members of the collaborative treatment teams in Saipan, San Francisco, San Diego and Portland. KMH received a 2017 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by Shire. KAB received funding from Henry's Fund to support her fellowship in haemostasis and thrombosis at Rady Children's Hospital San Diego. Funding Information: Thank you to the family who allowed us to share this case and to the members of the collaborative treatment teams in Saipan, San Francisco, San Diego and Portland. KMH received a 2017 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by Shire. KAB received funding from Henry's Fund to support her fellowship in haemostasis and thrombosis at Rady Children's Hospital San Diego. Funding Information: KAB, TLL and KMH have no interests, which might be perceived as posing a conflict or bias. CDT has received research support from Sanofi Genzyme, Novo Nordisk and Octapharma, travel funds for advisory meetings from Genentech and Biomarin, consulting fees for advisory board and Speaker's Bureau from Genentech and Biomarin, and consulting fees for data safety monitoring board participation from Sanofi Genzyme. CDT and KAB designed the manuscript. KAB wrote the first draft of the manuscript. CDT, TLL and KMH revised and approved the final version.
PY - 2020/11
Y1 - 2020/11
UR - http://www.scopus.com/inward/record.url?scp=85090219818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090219818&partnerID=8YFLogxK
U2 - 10.1111/hae.14133
DO - 10.1111/hae.14133
M3 - Letter
C2 - 32892446
AN - SCOPUS:85090219818
SN - 1351-8216
VL - 26
SP - e353-e355
JO - Haemophilia
JF - Haemophilia
IS - 6
ER -